Back to search
FDAFDA · Food and drugs·Recall number D-0094-2026

NAD+ (Nicotinamide adenine dinucleotide) for Injection, a) 100 mg/mL b) 200 mg/mL, 10 mL multi-dose amber vials, GenoGenix, LLC, 2840 NW 2nd Ave Ste 204 Boca Raton, FL 33431-6692.

Published October 15, 2025 · Recall initiated: July 30, 2025

Summary

FDA records drug Class I recall D-0094-2026, published October 15, 2025 and initiated July 30, 2025. Recalling firm: GenoGenix LLC; Status: Ongoing; Lot: Lot#: GG121624-023, within expiry. Class I means a reasonable probability of serious adverse health consequences or death.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Microbial Contamination of Sterile Products: elevated endotoxin levels

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
GenoGenix LLC
Distributor
US Nationwide.
Lot
Lot#: GG121624-023, within expiry
Risk classification
Class I
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was NAD+ (Nicotinamide adenine dinucleotide) for Injection, a) 100 mg/mL b) 200 mg/mL, 10 mL multi-dose amber vials, GenoGenix, LLC, 2840 NW 2nd Ave Ste 204 Boca Raton, FL 33431-6692. recalled?

Yes. FDA published recall D-0094-2026 on October 15, 2025. Reported hazard: Microbial Contamination of Sterile Products: elevated endotoxin levels

What should I do if I have this product?

Voluntary: Firm initiated · Letter